Cabotegravir And Rilpivirine: Efficacy and Safety Study

About CARES Trial

The CARES trial is a phase 3b, randomized, open label clinical trial evaluating the efficacy, safety, and tolerability of switching to cabotegravir long-acting (CAB LA) plus rilpivirine long-acting (RPV LA) in virologically suppressed HIV-1 infected adults on oral antiretrovirals in Sub-Saharan Africa.

The trial is sponsored by the Joint Clinical Research Centre (JCRC), Uganda and funded by Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), involving eight sites in Uganda, Kenya and South Africa.

This study builds on evidence from Europe and the United States on the effectiveness of long-acting cabotegravir/rilpivirine and its consequent approval by the WHO and the FDA for prophylaxis and treatment of HIV respectively. CARES will provide evidence and inform policy on the use of this therapy in treatment programs in Africa where the burden of HIV/AIDS is greatest.